SHL Telemedicine will proceed with the acquisition of the remaining 30% stakes in its Israeli subsidiaries Mediton and Medishur, despite filing an appeal against the court-mandated purchase price.
The company confirmed it will comply with the Israeli District Court’s ruling to finalize the takeover while simultaneously appealing the decision to the Supreme Court of Israel. Legal advisors to SHL argue the judgment contains material legal and factual errors in its valuation assessment.
The acquisition price for the 30% stake is set at 31.1 million new Israeli shekels, equivalent to approximately $8.3 million. SHL has already reserved the full amount, and the court ruling and subsequent completion of the transaction are not expected to have a material impact on the company’s financial position or earnings.
The transaction follows SHL’s announcement in March 2025 of its plan to acquire the remaining minority stakes in Mediton and Medishur. The initial 70% acquisition, completed in 2021, remains unaffected by the current legal proceedings.
